Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Replacing carbohydrates with monounsaturated fatty acids does not reduce blood pressure

13 Sep 2018

Substituting diets high in carbohydrates with those high in monounsaturated fatty acids (MUFAs) in the context of low saturated fatty acids do not appear to yield favourable effects on blood pressure, according to a meta-analysis.

Researchers conducted a systematic review of randomized controlled trials evaluating the effect of a >3-week intervention of high-MUFA diets in isocaloric substitution for high-carbohydrate diets on systolic blood pressure (SBP) and diastolic blood pressure (DBP). A total of 14 trials representing 980 participants were included in the meta-analysis.

Pooled data, performed using the generic-inverse variance method, revealed that the high-MUFA diets in isocaloric substitution for high-carbohydrate diets did not result in a greater reduction in blood pressure (SBP: mean difference [MD], −0.08 mm Hg; 95 percent CI, −1.01 to 0.84; p=0.86; DBP: MD, 0.01 mm Hg; −0.73 to 0.75; p=0.98).

Dose-response analysis showed neither linear nor nonlinear associations between increasing dose of MUFA substitution for carbohydrates and blood pressure outcomes.

Visual inspection of funnel plots revealed no evidence of a publication bias. This was confirmed by Egger’s and Begg’s tests, which showed no significant small-study effects for either SBP or DBP. The overall quality of the evidence was assessed as moderate.

According to researchers, the analysis may be considered surprising, given that current dietary cardiovascular disease recommendations indicate a 1-unit reduction in SBP in adults with BP ranging 120–159/80–95 mm Hg after replacing 10 percent of energy intake from carbohydrates with MUFA.

Researchers recommend that future meta-analyses consider adopting the individual participant data approach. Additional high-quality substitution trials focusing on carbohydrate quality and considering higher MUFA (%E) target are also needed.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.